Cargando…
Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes
BACKGROUND: Decreased monocytic (m)HLA-DR expression is the most studied biomarker of sepsis-induced immunosuppression. To date, little is known about the relationship between sepsis characteristics, such as the site of infection, causative pathogen, or severity of disease, and mHLA-DR expression ki...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082984/ https://www.ncbi.nlm.nih.gov/pubmed/32192532 http://dx.doi.org/10.1186/s13054-020-2830-x |
_version_ | 1783508450773303296 |
---|---|
author | Leijte, Guus P. Rimmelé, Thomas Kox, Matthijs Bruse, Niklas Monard, Céline Gossez, Morgane Monneret, Guillaume Pickkers, Peter Venet, Fabienne |
author_facet | Leijte, Guus P. Rimmelé, Thomas Kox, Matthijs Bruse, Niklas Monard, Céline Gossez, Morgane Monneret, Guillaume Pickkers, Peter Venet, Fabienne |
author_sort | Leijte, Guus P. |
collection | PubMed |
description | BACKGROUND: Decreased monocytic (m)HLA-DR expression is the most studied biomarker of sepsis-induced immunosuppression. To date, little is known about the relationship between sepsis characteristics, such as the site of infection, causative pathogen, or severity of disease, and mHLA-DR expression kinetics. METHODS: We evaluated mHLA-DR expression kinetics in 241 septic shock patients with different primary sites of infection and pathogens. Furthermore, we used unsupervised clustering analysis to identify mHLA-DR trajectories and evaluated their association with outcome parameters. RESULTS: No differences in mHLA-DR expression kinetics were found between groups of patients with different sites of infection (abdominal vs. respiratory, p = 0.13; abdominal vs. urinary tract, p = 0.53) and between pathogen categories (Gram-positive vs. Gram-negative, p = 0.54; Gram-positive vs. negative cultures, p = 0.84). The mHLA-DR expression kinetics differed between survivors and non-survivors (p < 0.001), with an increase over time in survivors only. Furthermore, we identified three mHLA-DR trajectories (‘early improvers’, ‘delayed or non-improvers’ and ‘decliners’). The probability for adverse outcome (secondary infection or death) was higher in the delayed or non-improvers and decliners vs. the early improvers (delayed or non-improvers log-rank p = 0.03, adjusted hazard ratio 2.0 [95% CI 1.0–4.0], p = 0.057 and decliners log-rank p = 0.01, adjusted hazard ratio 2.8 [95% CI 1.1–7.1], p = 0.03). CONCLUSION: Sites of primary infection or causative pathogens are not associated with mHLA-DR expression kinetics in septic shock patients. However, patients showing delayed or no improvement in or a declining mHLA-DR expression have a higher risk for adverse outcome compared with patients exhibiting a swift increase in mHLA-DR expression. Our study signifies that changes in mHLA-DR expression over time, and not absolute values or static measurements, are of clinical importance in septic shock patients. |
format | Online Article Text |
id | pubmed-7082984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70829842020-03-23 Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes Leijte, Guus P. Rimmelé, Thomas Kox, Matthijs Bruse, Niklas Monard, Céline Gossez, Morgane Monneret, Guillaume Pickkers, Peter Venet, Fabienne Crit Care Research BACKGROUND: Decreased monocytic (m)HLA-DR expression is the most studied biomarker of sepsis-induced immunosuppression. To date, little is known about the relationship between sepsis characteristics, such as the site of infection, causative pathogen, or severity of disease, and mHLA-DR expression kinetics. METHODS: We evaluated mHLA-DR expression kinetics in 241 septic shock patients with different primary sites of infection and pathogens. Furthermore, we used unsupervised clustering analysis to identify mHLA-DR trajectories and evaluated their association with outcome parameters. RESULTS: No differences in mHLA-DR expression kinetics were found between groups of patients with different sites of infection (abdominal vs. respiratory, p = 0.13; abdominal vs. urinary tract, p = 0.53) and between pathogen categories (Gram-positive vs. Gram-negative, p = 0.54; Gram-positive vs. negative cultures, p = 0.84). The mHLA-DR expression kinetics differed between survivors and non-survivors (p < 0.001), with an increase over time in survivors only. Furthermore, we identified three mHLA-DR trajectories (‘early improvers’, ‘delayed or non-improvers’ and ‘decliners’). The probability for adverse outcome (secondary infection or death) was higher in the delayed or non-improvers and decliners vs. the early improvers (delayed or non-improvers log-rank p = 0.03, adjusted hazard ratio 2.0 [95% CI 1.0–4.0], p = 0.057 and decliners log-rank p = 0.01, adjusted hazard ratio 2.8 [95% CI 1.1–7.1], p = 0.03). CONCLUSION: Sites of primary infection or causative pathogens are not associated with mHLA-DR expression kinetics in septic shock patients. However, patients showing delayed or no improvement in or a declining mHLA-DR expression have a higher risk for adverse outcome compared with patients exhibiting a swift increase in mHLA-DR expression. Our study signifies that changes in mHLA-DR expression over time, and not absolute values or static measurements, are of clinical importance in septic shock patients. BioMed Central 2020-03-20 /pmc/articles/PMC7082984/ /pubmed/32192532 http://dx.doi.org/10.1186/s13054-020-2830-x Text en © The Author(s). 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Leijte, Guus P. Rimmelé, Thomas Kox, Matthijs Bruse, Niklas Monard, Céline Gossez, Morgane Monneret, Guillaume Pickkers, Peter Venet, Fabienne Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes |
title | Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes |
title_full | Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes |
title_fullStr | Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes |
title_full_unstemmed | Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes |
title_short | Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes |
title_sort | monocytic hla-dr expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082984/ https://www.ncbi.nlm.nih.gov/pubmed/32192532 http://dx.doi.org/10.1186/s13054-020-2830-x |
work_keys_str_mv | AT leijteguusp monocytichladrexpressionkineticsinsepticshockpatientswithdifferentpathogenssitesofinfectionandadverseoutcomes AT rimmelethomas monocytichladrexpressionkineticsinsepticshockpatientswithdifferentpathogenssitesofinfectionandadverseoutcomes AT koxmatthijs monocytichladrexpressionkineticsinsepticshockpatientswithdifferentpathogenssitesofinfectionandadverseoutcomes AT bruseniklas monocytichladrexpressionkineticsinsepticshockpatientswithdifferentpathogenssitesofinfectionandadverseoutcomes AT monardceline monocytichladrexpressionkineticsinsepticshockpatientswithdifferentpathogenssitesofinfectionandadverseoutcomes AT gossezmorgane monocytichladrexpressionkineticsinsepticshockpatientswithdifferentpathogenssitesofinfectionandadverseoutcomes AT monneretguillaume monocytichladrexpressionkineticsinsepticshockpatientswithdifferentpathogenssitesofinfectionandadverseoutcomes AT pickkerspeter monocytichladrexpressionkineticsinsepticshockpatientswithdifferentpathogenssitesofinfectionandadverseoutcomes AT venetfabienne monocytichladrexpressionkineticsinsepticshockpatientswithdifferentpathogenssitesofinfectionandadverseoutcomes |